Previous 10 | Next 10 |
- Ended the quarter with $34.2 million in cash and investments with quarterly burn of $4.9 million - in line with Company projections - Cash expected to support operations through the end of 2024, including release of SAVVE topline data and TAVVE first-in-human study data IRVINE, CA / AC...
enVVeno Medical press release ( NASDAQ: NVNO ): FY GAAP EPS of -$2.20 beats by $0.01 . The Company ended the year with $39.1 million in cash and investments. Based on management's current expectations, the Company believes it has sufficient cash to sustain operations through t...
- Achieved more than half of enrollment in U.S. SAVVE pivotal trial of VenoValve® in 2022 - Multiple near-term milestones expected across VenoValve® and enVVe™ clinical programs - Ended the year with $39.1 million in cash and investments including $3.6 million burn for Q4...
Live video webcast presentation on Wednesday, March 8 th at 9:10 AM ET IRVINE, CA / ACCESSWIRE / February 8, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robe...
enVVeno Medical ( NASDAQ: NVNO ) announced the promotion of Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer. Dr. Alavi joined enVVeno Medical as Director, Research, Development and Quality in July 2020 and was promoted to Vice President of Rese...
Dr. Alavi is a highly accomplished medical device executive with proven track record of successfully leading R&D, Quality Assurance, Regulatory Affairs, and Manufacturing organizations across a number of companies within the cardiac and vascular space IRVINE, CA / ACCESSWIRE / January 18,...
- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, Jan...
First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 3 years post-surgery No venous ulcer recurrences or CVI relapses Stability in improvements for all study endpoints including reflux, disease severity (rVCSS), and pain (VAS) IRVINE, CA / ACCE...
The Company submitted safety data for the first 20 patients enrolled in the ongoing SAVVE U.S. pivotal study for the VenoValve Following the initial safety data review by the FDA, the SAVVE study is cleared to continue without modification or interruption The Company currently has ...
enVVeno Medical press release ( NASDAQ: NVNO ): Q3 Net Loss of $6.1M The company ended the quarter with $42.7 million in cash and cash equivalents, and investments. The company's burn rate for the third quarter was $4.5 million, in line with previous guidance of $4.0 -...
News, Short Squeeze, Breakout and More Instantly...
enVVeno Medical Corp Com Company Name:
NVNO Stock Symbol:
NASDAQ Market:
enVVeno Medical Corp Com Website:
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Thursday, June 27 th at 4:00 PM ET IRVINE, CA / ACCESSWIRE / June 25, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatmen...
91% of Venous Ulcer Patients Evaluated at One Year Have Either Fully Healed Ulcers or Ulcers That Have Improved 100% of Venous Ulcers with a Duration of One Year or Less Prior to VenoValve Surgery Have Fully Healed 89% of Venous Ulcers with a Duration of More Than One Year Prior to Veno...
IRVINE, CA / ACCESSWIRE / June 17, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that new interim venous ulcer healing data from the VenoValve U.S. pivotal trial will be ...